title: Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genes.
abstract: OBJECTIVE
  Decreased platelet responsiveness to acetylsalicylic acid (ASA) reported previously in diabetic patients could be attributed to patient-based, clinical, genetic and cellular factors. The objective of the present study was to investigate the effect of the genomic polymorphism on the platelet reactivity in diabetic patients treated with ASA.
  
  
  RESULTS
  The study cohort consisted of 295 Caucasians with diabetes type 2 who had been taking ASA tablets at the dose of 75 mg per day for at least 3 months for primary or secondary prevention of myocardial infarction (MI). Platelet reactivity analyzes were performed using VerifyNow ASA and PFA-100 assays. Genotyping for the selected 27 single nucleotide polymorphisms (SNPs) within 19 genes was performed using a Sequenom iPLEX platform. The results indicate that the statistically significant differences in platelet reactivity were observed in the PFA-100 assay for SNPs in following genes: TXBA2R (rs1131882), ADRA2A (rs4311994), PLA2G7 (rs7756935) and 9p21.3 (rs10120688) (P = 0.02, P = 0.03, P = 0.02, P = 0.03, respectively, all significance levels corrected for multiple comparisons). When using the VerifyNow ASA test, a weak nominal statistical significance (i.e. before multiple comparison testing) was observed for two SNPs in the GPVI gene: rs1671152 and rs1613662 [P = 0.025 (0.5) for both SNPs, corrected for multiple comparisons test].
  
  
  CONCLUSIONS
  The results from the present study suggest that the four analyzed genes may contribute to platelet reactivity measured with the PFA-100 assay in the diabetic population treated with ASA.
authors.affiliation: Department of Cardiology, Medical University of Warsaw, Poland. mpostula@wum.edu.pl
authors.forename: M
authors.initials: M
authors.lastname: Postula
authors.forename: A
authors.initials: A
authors.lastname: Kaplon-Cieslicka
authors.forename: M
authors.initials: M
authors.lastname: Rosiak
authors.forename: A
authors.initials: A
authors.lastname: Kondracka
authors.forename: A
authors.initials: A
authors.lastname: Serafin
authors.forename: K J
authors.initials: KJ
authors.lastname: Filipiak
authors.forename: A
authors.initials: A
authors.lastname: Czlonkowski
authors.forename: G
authors.initials: G
authors.lastname: Opolski
authors.forename: P K
authors.initials: PK
authors.lastname: Janicki
mesh_terms: D000368:Aged; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000235:genetics*; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D050505:Mutant Proteins; D015539:Platelet Activation / Q000187:drug effects / Q000235:genetics*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D010979:Platelet Function Tests; D011110:Polymorphism, Genetic; D020641:Polymorphism, Single Nucleotide
chemical_list: D050505:Mutant Proteins; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin